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Abstract 
Introduction 
Multiple CMR-derived indices of atrial fibrillation (AF) substrate have been shown in 
isolation to predict long-term outcome following catheter ablation. Left atrial (LA) 
fibrosis, LA volume, LA ejection fraction (EF), LVEF, LA shape (sphericity) and 
pulmonary vein anatomy have all been shown to correlate with late AF recurrence. 
This study aimed to validate and assess the relative contribution of multiple indices in 
a long-term single-center study. 
Methods and Results: 
89 patients (53% PAF, 73% male) underwent comprehensive CMR study prior to 
first-time AF ablation (median follow-up 726days (IQR 418-1010days)). 3D LGE 
acquisition (1.5T, 1.3x1.3x2mm) was quantified for fibrosis, LA volume and 
sphericity assessed on manual segmentation at atrial diastole, LA and LV ejection 
fraction (EF) quantified on multi-slice cine imaging. 
 











AF recurred in 43 patients (48%) overall (31 at one year). In the recurrence group, LA 
fibrosis was higher (42% vs 29%, HR 1.032, p=0.002), LAEF lower (25% vs 34%, 
HR 0.063, p=0.016) and LVEF lower (57% vs 63%, HR 0.011, p=0.008). LA volume 
(63 vs 61 ml/m2) and sphericity (0.819 vs 0.822) were similar. Multivariate Cox 
regression analysis was adjusted for age and sex (model 1), additionally AF type 
(model 2) and combined (model 3). In models 1 and 2, LA fibrosis, LAEF and LVEF 
were independently associated with outcome, but only LA fibrosis was independent in 
model 3 (HR 1.021, p=0.022). 
Conclusions: 
LAEF, LVEF and LA fibrosis differed significantly in the AF recurrence cohort. 
However, on combined multivariate analysis only LA fibrosis remained 
independently associated with outcome. 
Key Words 
Atrial fibrillation, cardiac magnetic resonance imaging, structural remodeling, atrial 
fibrosis, catheter ablation 
Introduction 
Catheter ablation is an effective treatment for appropriately selected patients with 
atrial fibrillation (AF) 1. What constitutes appropriate selection, however, remains 
poorly understood and vigorously debated. CMR permits assessment of left atrial 
(LA) structural remodeling (SRM), and consequent associated likelihood of 
procedural success. Several CMR-derived indices of LA SRM have been proposed 
and validated in isolated studies, but the interaction and additive value of these 
indices has not been established. The following CMR-derived indices were 
hypothesized to be independently predictive of outcome following ablation: 
 











(i) Pre-ablation LA fibrosis quantification. Late gadolinium enhanced (LGE) imaging 
of the atrial wall, generally accepted to represent intramural fibrosis, is the most 
widely researched index of LA SRM 2–4, but the reliability of implementation between 
centers is controversial5. An independently derived quantification method, based on 
an image intensity ratio 4, was developed for this study. 
(ii) LA size. CMR imaging may be used to assess atrial volume, calculated from 
multi-slice cine imaging or segmentation of a 3D volumetric dataset, and has been 
shown to be associated with long-term AF recurrence 6,7. 
(iii) LA function. LA systolic function is challenging to quantify on echocardiographic 
imaging, but is relatively reliably assessed on CMR imaging. LA total ejection 
fraction (LAEF) has been found on multivariate analysis to be independently 
associated with outcome, and was therefore included as the index of LA function 8.  
(iv) Left ventricular (LV) function. AF may be both a cause and effect of LV systolic 
dysfunction and has also been shown to be associated with an increased risk of AF 
recurrence in some, but not all, studies 6,9.  
(v) LA shape. Bisbal et al 10 defined an LA sphericity index, derived through 
quantitative comparison of the segmented LA body (defined on an ungated CMR 
angiogram) to a sphere, which was found to be strongly predictive of AF recurrence.  
(vi) Pulmonary venous (PV) anatomy. PV anatomy is reliably identified on CMR 
imaging and it has been shown that there is a reduced risk of recurrence in those with 
a single left sided PV (13% versus 34%) 11.  
This study aimed to combine the key CMR-derived indices in a detailed assessment of 
their relative reliability and independence of predictive value, with an aim to create a 
 











single, weighted, model for testing in future cohorts. The study was performed within 
a single center real-world environment with long term (2 year) follow-up.  
Methods 
Patients 
Patients planned for first-time AF ablation procedure were referred for pre-procedural 
clinical CMR scan, from January 2014 to October 2015. Paroxysmal (PAF) and 
persistent AF (PersAF) were defined as per HRS/EHRA guidelines 1. Patients who 
underwent subsequent cryoablation (n=1) or did not receive gadolinium-based 
contrast agent (n=2, one previous allergic reaction, one patient choice) were excluded. 
Patients were included regardless of rhythm at the time of scan. 
CMR imaging acquisition 
CMR imaging was performed on a 1.5T MR-scanner (Ingenia, Philips Healthcare, 
Best, Netherlands). Cine imaging was performed in end-expiration using a standard 
multislice bSSFP technique (effective TR 2.7msec, TE 1.3msec, 1.25x1.25mm2 in-
plane, slice thickness 10mm, 50 phases). The 3D inversion recovery spoiled gradient 
echo (LGE) acquisition was performed with coverage to include the whole of the LA 
in axial orientation. (TR 5.5msec, TE 3.0msec, flip angle 25° low-high k-space 
ordering, respiratory and ECG gated (end atrial diastole, maximum 120msec 
window), 1.3x1.3x4mm3 acquired resolution with 2mm slice overlap, SPIR fat 
suppression).  
Fibrosis assessment 
Analysis was performed on an MITK-based platform (German Cancer Research 
Centre, Heidelberg, Germany), with custom-build modifications to enable the 
quantification of atrial fibrosis. The LA endocardial surface was defined via manual 
 











segmentation within the 3D LGE volume. A 2mm surface dilation was used to define 
the epicardial border, in keeping with established methods 4, and a mean intensity 
projection technique was used to ascribe a single signal intensity value to each point 
on the LA endocardial surface model. The mitral valve, distal PVs (2mm distal to 
antrum) and LA appendage were removed using Paraview (Clip filter, Kitware, New 
York, NY, USA) and the surface was re-extracted as a binary file (Figure 1A and B). 
Further details are available in the online supplement (Supplementary Figure 1). 
LA scar burden was quantified using an image intensity ratio threshold (0.97 times 
mean blood pool (BP) signal intensity (SI) 4). BP SI was measured for a 4ml spherical 
volume placed in the center of the LA blood pool, distant from potential artefacts 
including respiratory navigator induced inflow signal. For reproducibility assessment, 
43 LGE volumes were re-segmented independently by a separate observer (WS) and 
quantified using the same technique.  
Left atrial size 
LA size was assessed in atrial diastole at maximum volume. The LA was manually 
segmented from the 3D LGE volume, excluding the LAA and PVs. The volume of the 
segmentation was assessed using ITK-snap (Version 3.4.0, University of 
Pennsylvania, USA). For reproducibility assessment, 45 LGE volumes were re-
segmented independently by a separate observer (WS). 
Left atrial and left ventricular function 
LA and LV function were assessed on multi-slice short-axis cine imaging stack, using 
a conventional manual chamber contouring technique (ViewForum (Philips 
Healthcare, Best, Netherlands)). The LA was manually contoured at maximum 
volume (LAVmax (end atrial diastole)), and minimum volume (LAVmin (end atrial 
 











systole)), with the LAA and PVs excluded. LAEF was defined as total LA emptying 
fraction ((LAVmax-LAVmin)/LAVmax). For patients in AF during the scan, the 
minimum and maximum volume time phases were manually selected and assessed. 
For reproducibility assessment of LA function, 45 patients underwent independent 
measurement by a separate observer (JG). Reproducibility was not assessed for 
LVEF.  
Atrial sphericity 
LA sphericity was calculated according to the methods of Bisbal and co-workers 
(2013) 10. The LA body was manually segmented on the 3D LGE acquisition on a 
slice-by-slice basis on the MITK platform, excluding the LAA and PVs. A VTK shell 
was created from the segmentation, and sphericity quantification performed using the 
algorithms published by the Barcelona group 10 (Figure 1C). For reproducibility 
assessment, 45 LGE datasets were re-segmented by an independent observer (WS). 
Pulmonary venous anatomy 
PV anatomy was assessed on the 3D LGE dataset. They were classified as normal (2 
left and 2 right veins), single left (with any combination of right sided veins), isolated 
three right sided veins (with 2 left sided veins), or any other pulmonary venous 
arrangement. 
Atrial fibrillation ablation procedure 
Two experienced operators performed all procedures under general anaesthesia using 
Carto3 (Biosense Webster/Johnson&Johnson, New Jersey, USA) electroanatomic 
mapping system, with the exception of 8 procedures performed using EnSite Velocity 
(St Jude Medical, St Paul, Minnesota, USA). For patients with a diagnosis of PAF and 
in sinus rhythm, a point-by-point wide area circumferential ablation (WACA) 
 











achieving PV isolation (PVI) was performed using 8Fr irrigated SmartTouch catheter 
(Biosense Webster), or 8Fr irrigated TactiCath catheter (St Jude). Target ablation 
parameters were >5g for at least 15 seconds per RF delivery location. Power was 30W 
throughout except on the posterior wall, where it was limited to 25W. Procedural 
endpoint was defined as PV isolation as confirmed on entry block (and exit block if 
capture achieved). Adenosine was not used routinely to test isolation and waiting time 
of 30 minutes after final PV isolation was respected in all patients. For patients 
presenting with PersAF, a WACA was performed followed by additional ablation 
lesion sets (mitral line, roof line, inferior posterior line, complex fractionated 
electrogram ablation) as a step-wise ablation 12). Overall, 27 had a roof line (4 with 
incomplete block), 18 a mitral line (one with incomplete block), 12 a low posterior 
line (one with incomplete block), and 9 had further CFAE ablation. If AF converted 
to atrial tachycardia, this was mapped using conventional electroanatomic and 
entrainment techniques and ablation targeted to the arrhythmia mechanism. If AF 
terminated to sinus rhythm, no further ablation was performed other than to confirm 
PVI and linear conduction block. 
All patients who underwent ablation had failed at least one antiarrhythmic drug prior 
to ablation. For patients taking antiarrhythmic medication up to shortly before 
ablation (73 patients, 82%), the drug was continued up to 3 months post ablation. 
Final medications prior to ablation included betablocker for 43 subjects (48%, most 
commonly bisoprolol), calcium channel blocker (7 (8%)), type 1c sodium channel 
blocker (19 (21%) most commonly flecainide), sotalol (9 (10%)), digoxin (4 (4%)), 
and amiodarone (11 (12%)), with 20 patients on >1 antiarrhythmic. For patients who 
had discontinued ineffective antiarrhythmic medication prior to ablation, further 
 











medication was only prescribed in the event of an arrhythmia recurrence following 
ablation. 
Subject follow-up 
Recurrence of AF post-ablation was defined as a recurrence of AF (>30seconds), or 
episodes of atrial tachycardia or atrial flutter, in line with HRS/EHRA guidelines 1. 
Follow-up was at 3months post-ablation, with symptom review, 24 hour tape and 12-
lead ECG performed. Subsequently, patients were typically reviewed at 6 and 
12months after the index procedure, and yearly thereafter. A 12-lead ECG ± Holter 
monitor was performed at each review, in the absence of reported symptoms. If 
symptoms were reported, patients underwent 12-lead ECG, Holter monitor or event 
monitor assessment, according to symptom frequency. Patients without recurrence 
were censored at the time of the last available follow-up and a blanking period of 
three months was employed post ablation. In the presence of continued arrhythmia 
recurrence outside of the blanking period, the timing of recurrence was dated to the 
earliest documented arrhythmia post-ablation.  
Statistics 
Normally distributed continuous variables are presented as mean ± standard deviation, 
and median with interquartile range (IQR) for non-normal distribution or non-
continuous ordinal data. Time to AF recurrence was related to the individual 
demographic and CMR covariates using separate univariable Cox proportional hazard 
regression models. Primary analyses were performed to censoring at one year, or at 
the date of last contact for those patients who were lost to follow-up prior to day 365. 
Kaplan-Meier survival curves were compared using Mantel-Cox test with analyses 
including each patient’s complete follow-up period. Where there were no clear 
 











grounds for dichotomization of an index, high and low index populations were 
defined arbitrarily at above and below the median respectively. Multivariate Cox 
proportional-hazards models were used to assess the association of pre-determined 
indices against arrhythmia recurrence, and results are presented as hazard ratio (HR) 
with 95% confidence interval. Two initial models were employed, adjusting for age 
and sex (Model 1) and age, sex and AF type (paroxysmal versus non-paroxysmal AF, 
Model 2). A final stepwise multivariate model (Model 3) was adjusted as for Model 2 
and used all indices with p<0.05 in Model 2. Graphical assessment of Schoenfeld 
Residuals and log-log plots was used to exclude time-dependency of co-variates and 
violation of proportional hazards assumption. For receiver operator characteristic 
curves, outcomes were censored at 6months, 1 year and 2 years, and binomial logistic 
regression performed at 6months only. Statistics were analysed using SPSS Statistics 
(Version 25, Armonk, NY) and Stata (Version 15.1, Statacorp). 
Ethics 
All pre-ablation CMR studies were clinically indicated, and ethical approval for 
retrospective analysis was obtained (REC reference 09-H0802-78). 
Results 
Patients 
In total, 89 subjects underwent full CMR prior to routine first-time ablation, and 
baseline demographics and associated hazard ratios for AF recurrence are detailed in 
Table 1. Median total follow-up time was 726 days (IQR 418-1010days), and there 
were 43 (48%) recurrences by final follow-up, at median 150 days (IQR 79-378days). 
Two patients were lost to follow-up prior to 6 months post ablation (at 165 and 175 
days respectively, no recurrence) and a further 10 patients prior to one year post 
ablation (at 184, 188, 190, 245, 253, 256, 285, 301, 325 and 334 days respectively, no 
 











recurrence). Kaplan-Meier survival curves for baseline parameters are presented in 
Supplementary Figure 2. CMR imaging was completed for all subjects for all indices, 
with the exception of three subjects for whom atrial fibrosis could not be assessed 
(poor myocardial nulling in two, and unacceptable artefact in one).  
CMR-derived indices 
CMR-derived indices are summarized in Table 2, and associated Kaplan-Meier plots 
shown in Figure 2.  
The simplest, separate, multivariate analyses of the indices (Model 1) adjusted for age 
and sex alone, whilst Model 2 additionally adjusted for AF-type (binary: PAF/non-
PAF). For both models, atrial fibrosis, LAEF and LVEF were all independently 
associated with recurrence (Table 3). In Model 3, the combined multivariate analysis 
of those three significant indices, atrial fibrosis was the only factor independently 
associated with recurrence (HR 1.021, p=0.022). Detailed analysis of index 
collinearity and confounding variables is presented in the online supplement 
(supplementary Figures 3-5 and supplementary Table 2). In total, 36 subjects were 
imaged in AF, and for these patients functional parameters were significantly reduced 
[LAEF: 20±11% versus 38±15% (p<0.0001), LVEF: 55±9% versus 64±10% 
(p=0.0002)], whilst there was no significant difference in LA fibrosis [37±17% versus 
31±20%, p=0.16]. The univariate analysis of each parameter in sinus rhythm and AF 
respectively are presented in Supplementary Table 1. There was no clinically relevant 
correlation between degree of severity of LA fibrosis or LAEF and time to recurrence 
(R2=0.0004 and 0.010 respectively). 
Reproducibility of the CMR-derived indices was also assessed, and the results are 
presented in full in the online supplement (Supplementary Figure 5). Interobserver 
 











Lin’s concordance correlation coefficients were 0.866 (95% CI 0.787-0.917) for LA 
fibrosis, 0.923 (95% CI 0.873-0.954) for indexed LA volume, 0.860 (95% CI 0.779-
0.912) for LAEF and 0.906 (95% CI 0.842-0.945) for sphericity. 
Predictive value 
Figure 3 shows receiver operator characteristic curves for the five CMR indices, with 
outcomes censored at 6 months (26 recurrences in total). A binomial logistic 
regression was performed to ascertain the combined effects of the CMR parameters 
(atrial fibrosis, LAEF, LVEF, indexed LA volume) on the likelihood of arrhythmia 
recurrence; sphericity was excluded to avoid overfitting of the data. The logistic 
regression model was statistically significant, χ2(4)= 12.5 (p=0.014) and explained 
19% (NagelKerke R2) of the variance in arrhythmia recurrence, correctly classifying 
79% of cases (Table 4). Area under the curve (AUC) at 6months was 0.711. The 
predictive value of each index shifted with time, and ROC curves for each index at 1 
year and 2 years are presented in Supplementary Figure 6; AUC for the combined 
model was 0.780 at 1 year and 0.760 at 2 years. 
Discussion 
The long-term outcome following AF ablation is excellent in selected patients, but for 
others the outcome remains suboptimal and improved patient selection may increase 
interventional success rates. Multiple CMR indices have been shown to be associated 
with long-term outcome but their implementation in parallel has never been 
demonstrated. Furthermore, many CMR studies have excluded patients in AF, the 
very group that stands to benefit most from accurate stratification. This study has 
taken a real-world cohort of first-time AF ablation patients, and performed follow-up 
for a median 2 years. The key findings are: 
 











1. LA fibrosis is independently associated with long-term outcome, as assessed 
by arrhythmia recurrence 
2. LAEF, LVEF and indexed LA volume are significantly associated with 
outcome, but the associations are not independent 
3. LA sphericity, using the assessment methods of this study, is not associated 
with outcome. 
Comparison with prior studies 
LA fibrosis has been proposed as a powerful risk stratification modality for patients 
under consideration for AF ablation. However, implementation of the technique 
outside of centers in Utah and Johns Hopkins 2,3,13 has been limited, and widespread 
adoption of the technique has been hindered by the requirement for imaging 
specialists and image processing teams using bespoke software and considerable 
experience 1,3,5. This study has implemented a relatively streamlined approach in the 
assessment of LA fibrosis, aiming to replicate a mainstream image thresholding 
technique 4 using tools that can be made freely available to other centers. LA fibrosis 
scores in this study are similar to those found by the Johns Hopkins group 
(33.5±18.8% and 35.9±14.8% respectively), as was the hazard ratio per % increase in 
fibrosis in this study (1.032, 95% CI 1.013-1.052, versus 1.05 4).  
LAEF, LVEF and indexed LA volume have been shown to be associated with 
outcome in other studies 6,7,14. In this combined assessment, the associations were 
replicated, but they were not shown to be independent. To some extent, the findings 
here are in concordance with the recent findings of den Uijl and colleagues7: on 
assessment of a more limited set of CMR parameters (LA fibrosis, LA size and LA 
sphericity) with shorter follow-up, they found that only one parameter was associated 
 











with recurrence on stepwise multivariable analysis. However, for their study the 
predictive variable was LA size and the methodological differences are important. In 
particular, it is not clear whether atrial volumes were assessed in systole or diastole, 
and scar was thresholded at IIR 1.20 rather than 0.97, resulting in a much lower 
median fibrosis burden of 6%. In the absence of a clear gold standard for 
quantification of atrial fibrosis, and mean fibrosis burdens varying widely in 
apparently similar patient cohorts (for reference, the mean fibrosis in the DECAAF 
study was 18.1%3), further comparisons between analysis techniques are required. 
In this study, LA sphericity demonstrated no association with AF ablation outcome, in 
contrast to the findings of the original publication 10. The absence of association with 
outcome may be related partly to the method of assessment. The Barcelona group 
assessed sphericity using a non-ECG-gated CMR angiogram acquisition, acquiring in 
atrial systole or diastole, whereas in this study the sphericity was assessed at a 
uniform point in the cardiac cycle, in atrial diastole. However, derived sphericity 
scores for this study and the Barcelona study were very similar (PAF: 81.1±3.2 versus 
81.4±2.95 and PersAF: 83.3±3.3 and 82.8±3.4 respectively), as was the reliability of 
the measure (interobserver concordance correlation coefficient 0.91 versus 0.94, see 
online supplement). The sphericity index may be more important when assessed in 
atrial systole, but this is dependent upon imaging in sinus rhythm.  
Clinical implementation 
The aim of the study was to implement multiple CMR indices for AF recurrence post-
ablation, with a view to generating a synergistic, weighted, risk score for future 
validation, based on all parameters and derived from a single imaging procedure. 
However, in this patient cohort only LA fibrosis was independently associated with 
 











outcome. Interobserver variability in measurement was relatively low (see online 
supplement), but the study may have been underpowered to detect the impact of 
LAEF, LVEF and indexed LA volume.  
The most useful clinical outcome would be a reliable predictor for patients highly 
unlikely to benefit from a standard ablation procedure. In this study, a fibrosis cut-off 
of 50% had a positive predictive value for recurrence by six months of 67%, and 
negative predictive value 79%. However, excluding this high fibrosis cohort would 
risk 33% of those patients not having a procedure from which they might otherwise 
derive substantial benefit, and only 17 patients (20%) fell into this high fibrosis group. 
A CMR-derived prediction of outcome, though, may enable patients to make a 
decision on the appropriateness of ablation for them based upon the likelihood of 
long-term freedom from AF, rather than a short-term effect, so long as the uncertainty 
in the prediction is adequately explained. 
Larger studies may show that combining LA fibrosis with other CMR-derived indices 
improves predictive value. Combination with other CMR indices such as atrial T1 
mapping 15, LV scar 16, ventricular post-contrast T1-mapping 17, and PV size 18 may 
also improve overall performance, but were not investigated in this study. However, a 
multimodality score is most likely to achieve the highest precision, and other non-
invasive non-CMR indices including surface ECG dominant frequency 19 and LA 
deformation patterns on echocardiography 20 may be combined with invasive 
characterization such as voltage mapping 21 in order to optimize ablation strategies 
through the identification of a high-performance biomarker. 
 












This study aimed to implement a ‘real-world’ assessment of CMR-derived indices, 
and it is important that limitations should be acknowledged. Firstly, the cohort size, 
and in particular the number of recurrences (26 (30% of non-censored patients) at 6 
months, 31 (40%) at one year, and 37 (64%) at 2years), is small for the evaluation of 
multiple indices. However, the use of a single center with extended follow-up was 
important to minimize inter-procedural variations. Criteria for progressing from PVI 
alone to more extensive ablation strategies were dependent upon patient and 
electrophysiological findings, and were not determined by CMR indices, but ablation 
strategies have evolved with time: it is no longer our practice to perform CFE ablation 
in an effort to terminate AF. 
This study has used the most widely employed recurrence definitions, in the context 
of thorough clinical follow-up, but brief recurrences that may have been captured by 
more comprehensive monitoring strategies are likely to have been missed. 
The method used to quantify atrial fibrosis was derived from that of the Johns 
Hopkins group, and demonstrated similar average scores and hazard ratio, but has not 
been independently validated against voltage or histology. Atrial fibrosis 
quantification remains difficult to reproduce between centers, and it should be noted 
that some well-designed, rigorous, studies have failed to show an association with 
outcome5. 
Imaging quality is generally inferior in the presence of arrhythmia, and LAEF in 
particular varied between sinus rhythm and AF (see online supplement). Furthermore, 
those in AF during CMR may be more prone to atrial wall movement artefact, and 
hence inclusion of the atrial blood pool in the atrial wall voxels, artificially increasing 
 











the fibrosis score. However, a risk stratification method needs to be as inclusive as 
possible, and elimination of subjects in AF is not generally feasible. Several previous 
studies of atrial fibrosis have included a proportion of patients in AF (generally 10-
30%)2,3,5,13 DC cardioversion can clearly be coordinated with CMR assessment, but 
the time-dependent impact of cardioversion on LV and LA function has not been 
detailed, and the longer the CMR scan is delayed post-cardioversion, the more likely 
the arrhythmia is to recur.  
Conclusion 
In this study, the individual and combined predictive value of CMR-derived indices 
for AF recurrence post-ablation were evaluated. In a real-world cohort, only LA 
fibrosis was found to be independently associated with outcome. An effective 
biomarker for AF ablation stratification and tailoring of treatment is required, but this 
study suggests that CMR can perform only a partial evaluation of the atrial substrate. 
Combinations of multimodality indices or more sophisticated tissue characterization 
techniques are required in order to further improve pre-ablation assessment.  
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Figure 1. Illustration of left atrial fibrosis quantification and sphericity 
assessment. 
(A) Low fibrosis left atrium (LGE-18% (left)), with atrial shell thresholded at 
image intensity ratio (IIR) 0.97. (B) High fibrosis left atrium (74%), white 
arrows indicating regions of LA wall enhancement (C) (Left) multiplanar 
reconstruction of 3D LGE dataset, with LA body-only segmentation, and (right) 
sphericity calculation. For this subject, sphericity was 88.6%. 
 
 











Figure 2. Kaplan Meier survival curves for CMR indices.  
Each parameter has been dichotomised (except pulmonary vein anatomy). 
Number of subjects in each group at the start of follow-up shown at the end of 















Figure 3. Receiver operator characteristic curves (left sided panels) and index 
distribution between subjects with recurrence and no recurrence (right sided 
panels) at 150days post procedure. 
AUC: Area under curve. CI: confidence interval  
 
 












Table 1. Baseline demographics and findings. 
Hazard ratios calculated on univariate Cox regression analysis. AF: atrial 
fibrillation, BMI: body mass index. Significant comorbidity defined as Charlson 
comorbidity index ≥ 1 22 
  All Subjects 
(n=89) 
Hazard ratio for AF recurrence 
(95% CI) p-value 
Male Sex 65 (73%) 1.34 
(0.67-2.7) 
0.40 
Non-paroxysmal AF 41 (47%) 2.3 
(1.25-4.3) 
0.008 







26 (29%) 1.02 
(0.56-1.88) 
0.92 




















Age (years) 59.6 ±11.0 1.007 
(0.98-1.03) 
0.59 
Weight (kg) 88.4±15.9 0.999 
(0.98-1.02) 
0.93 
BMI (kg/m2) 28.7±4.8 0.97 
(0.91-1.03) 
0.34 
LV Mass (g) on CMR 111±31 0.995 
(0.98-1.004) 
0.30 


























































































Table 3. Multivariable Cox regression analysis of the association of established 
CMR indices with arrhythmia recurrence.  
For Model 1 and 2, each row represents a separate multi-variable analysis. 
Model 1 is adjusted for age and sex alone, Model 2 additionally for AF type 
(binary: PAF/non-PAF). Model 3 contains all factors of Model 2, and the three 
significant CMR derived indices, in a single multivariate analysis. EF: ejection 
fraction, HR: Hazard Ratio, CI: confidence interval. 
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Table 4. Classification table for binomial logistic regression analysis of arrhythmia 















Recurrence 15 11 
Sensitivity 
42% 
 
Negative 
predictive 
value 
79% 
Positive 
predictive 
value 
79% 
Accuracy 
78.6% 
 
